Cambridge Cognition Holdings PLC- Cambridge, neuroscience technology company - Wins contract with an unnamed "top 10" pharmaceutical company. The contract worth over GBP1 million will see Cambridge Cognition provide digital cognitive assessments for a phase III autoimmune disease trial. Revenue from the contract is expected over the next three years.
"Strategically, this contract sees the company operate in a high growth space with a leading pharmaceutical company that is committed to tackling diseases in this therapeutic area," says Matthew Stork, Chief Executive Officer of Cambridge Cognition.
Current stock price: 140.00 pence, up 15% on Monday
12-month change: up 65%
By Tom Budszus; tombudszus@alliancenews.com
Copyright 2022 Alliance News Limited. All Rights Reserved.
Cambridge Cog (COG)